Lucid Diagnostics (LUCD) Earnings Date & Reports

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

LUCD is expected to report earnings to fall 12.50% to -5 cents per share on November 16

Lucid Diagnostics LUCD Stock Earnings Reports

Q3'26

Est.

$-0.05

Q2'26

Est.

$-0.06

Q1'26

Est.

$-0.07

Q4'25

Missed

by $0.01

Q3'25

Beat

by $0.01

The last earnings report on August 13 showed earnings per share of -5 cents, meeting the estimate of -5 cents. With 1.56M shares outstanding, the current market capitalization sits at 153.85M.

View a ticker or compare two or three

LUCD

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for LUCD